Lantheus’ AI software aPromise for assessing prostate-specific membrane antigen PET/CT exams is now available on Siemens Healthineers’ syngo.via platform.
aPromise is a U.S.-cleared deep learning algorithm that provides quantitative total disease burden on F-18 DCFPyL (Pylarify) PET/CT images. Recent clinical studies have shown that total quantitative burden with aPromise supports patient selection for prostate cancer radioligand therapy and automates monitoring response over time, Lantheus said.
Siemens Healthineers will be demonstrating the integrated solution at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Toronto to be held June 8 to 11, Lantheus noted.



![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)







![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)






